Information Provided By: 
Fly News Breaks for July 17, 2017
NVO, LLY
Jul 17, 2017 | 06:22 EDT
Piper Jaffray analyst Richard Purkiss is highlighting the "remarkable growth story" of Eli Lilly's (LLY) once-weekly GLP-1 agonist Trulicity for type 2 diabetes. At its current pace, Trulicity would become market leader in the GLP-1 space in the early part of next year, surpassing Novo Nordisk's (NVO) Victoza, Purkiss tells investors in a research note. He views Lilly's launch as "quite simply unique in the current climate." Lilly remains one of the analyst's top 2017 picks with an Overweight rating and $102 price target.
News For LLY;NVO From the Last 2 Days
NVO
Apr 24, 2024 | 15:59 EDT
Senator Bernie Sanders is set to lead a Senate investigation into the high prices charged by Novo Nordisk for its diabetes and anti-obesity medications Ozempic and Wegovy, The Financial Times' Oliver Barnes reports. Sanders wrote to Novo Nordisk CEO Lars Fruergaard Jorgensen to inform him the U.S. committee that oversees healthcare is probing "the outrageously high prices" the company charges for the drugs, saying that the drugs "will not do any good for the millions of patients who cannot afford them." Reference Link
